Drugs / SH006
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07362264 | Jul 2025 → Dec 2026 expected | liver cancer | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07392866 | Mar 2026 → Mar 2030 expected | hepatocellular carcinoma | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SH006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07392866 ↗ |
| Route | Intravenous | “administered as IV infusion” NCT07392866 ↗ |